Elizabeth Sconce
Emerita Professor Ann Daly
Dr Tayyaba Khan
Dr Hilary Wynne
Professor Farhad Kamali
et al. | APOE genotype makes a small contribution to warfarin dose requirements | 2006 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al. | Apolipoprotein E polymorphisms do not make a clinically significant contribution to warfarin dose requirements | 2006 |
|
Dr Hilary Wynne
Dr Tayyaba Khan
Dr Peter Avery
Peter Wood
Professor Farhad Kamali
et al. | Dietary related plasma vitamin C concentration has no effect on anticoagulation response to warfarin | 2006 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al. | Simvastatin results in a lower warfarin dose requirement due to a reduced clearance of warfarin | 2006 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Emerita Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al. | The impact of simvastatin on warfarin disposition and dose requirements | 2006 |
|
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
| [abstract] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism | 2005 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Patrick Kesteven
Dr Peter Avery
et al. | [abstract] Pfizer poster communication prize - The influence of patient age, CYP2C9 genotype and height on warfarin dose requirements | 2005 |
|
Dr Tayyaba Khan
Elizabeth Sconce
Professor Farhad Kamali
| Factors contributing to the stability of anticoagulation control and outcome of thromboembolic prophylaxis in the older population | 2005 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Professor Farhad Kamali
| Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation | 2005 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Professor Farhad Kamali
| Patients with unstable control have a poorer dietary intake of vitamin K compared with patients with stable control of anticoagulation | 2005 |
|
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Peter Avery
Dr Barry King
et al. | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen | 2005 |
|
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Dr Patrick Kesteven
Peter Wood
et al. | Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin | 2004 |
|
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Peter Avery
Dr Patrick Kesteven
Professor Farhad Kamali
et al. | Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin | 2004 |
|
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Professor Ann Daly
Dr Hilary Wynne
et al. | The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements | 2004 |
|
Dr Tayyaba Khan
Professor Farhad Kamali
Dr Patrick Kesteven
Dr Peter Avery
Dr Hilary Wynne
et al. | The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation | 2004 |
|
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Emerita Professor Ann Daly
| Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism | 2004 |
|
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
| Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements | 2003 |
|
